BMO Capital analyst Evan Seigerman raised the firm’s price target on Regeneron (REGN) to $725 from $640 and keeps an Outperform rating on the shares after its better than expected results. Regeneron’s ability to translate R&D spend to EV growth should not be underestimated, as its productivity is the basis for long-term success, the analyst tells investors in a research note. BMO adds that the company could finally be nearing an end of the manufacturing issues that have plagued the Eylea HD franchise since 2023.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on REGN:
